Author of

• 34731

  +

  P35 - Pathology - Genomics (ID 105)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 34756

    +

    P35.21 - Comprehensive Genomic Profiling of Lung Metastases in Cancer Patients (ID 1491)

    00:00 - 00:00  |  Presenting Author(s): Li Wang
    • Abstract
    • Slides

    Introduction
    

    Lung is one of the most common sites of cancer metastases. However, the molecular characterization of the lung metastases in patients with different tumor types remained unclear.

    Methods
    

    Tissue samples of the lung metastases were obtained from patients with solid tumors other than lung cancer. Targeted next-generation sequencing (NGS) with a panel of over 381 cancer genes was performed on the lung metastases in 3DMed laboratory.

    Results
    

    A total of 184 lung metastases samples were screened and included for analysis. The sites of origin included colorectal cancer (n=51), breast cancer (n=24), gynecologic cancer (n=20), sarcoma (n=17), kidney cancer (n=14), head and neck carcinoma (n=14), and hepatocellular carcinoma (n=13), etc. In overall, the most frequently mutated genes fell in TP53 (54.9%), KRAS (21.2%), APC (19.0%), PIK3CA (16.8%), PTEN (7.1%), ERBB2 (6.5%), CDKN2A (5.4%), and VHL (5.4%). Distinct molecular mutational patterns were observed in lung metastases from different tumor types. Lung metastases from colorectal cancer exhibit the highest prevalence of gene alterations (TP53, 92.2%, APC, 62.7%, and KRAS, 58.8%), followed by breast cancer (TP53, 70.8%, PIK3CA, 45.8%, ERBB2, 25%, and MCL1, 25%), hepatocellular carcinoma (TP53, 69.2% and AX1N1, 30.8%) and renal carcinoma (VHL, 57.1%). The lowest mutation prevalence were obtained from the lung metastases from gynecologic cancer (PIK3CA and TP53, 30% for each), head and neck carcinoma (TP53, 35.7% and PIK3CA, 28.6%), and sarcoma (FRS2 and MDM2, 23.5% for each). Amongst all, mutations in EGFR kinase domain were found only in two lung metastases samples, with one patient with primary urothelial cancer and the other one with primary melanoma. The other sensitizing mutations in the driver genes of lung cancer were rarely observed, including ALK fusion (ALK-SMYD3) in one 34-year-old female with primary clear cell renal cell carcinoma, MET gain in one male with primary hepatocellular carcinoma, and RET fusion (KIF5B-RET) in one female with primary neuroendocrine carcinoma.

    Conclusion
    

    In general, the mutational patterns of the lung metastases were more likely to depend on that of the corresponding primary tumors. A subset of patients harboring lung cancer related targetable driver mutations in the lung metastases may benefit from targeted TKIs therapies.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.